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ABSTRACT 
Introduction:  Bronchopulmonary dysplasia (BPD) is common sequaelae of premature birth.  
It can be complicated by the development of pulmonary hypertension (PH), which 
significantly increases mortality. Areas covered: The aim of this review is to evaluate 
emerging drug therapies for prevention and treatment of BPD and associated PH. These 
include superoxide dismutase, macrolides, Clara secretary cell protein, -1 protease 
inhibitors, pentoxifylline, melatonin, inositol, N-acetyl cysteine, allopurinol, cimetidine, 
pulmonary vasodilators and mesenchymal stem cells (MSC).  We have also included 
discussion on longer standing therapies such as corticosteroids, caffeine and vitamin A. 
Expert opinion:   Corticosteroid administration systemically, but not by inhalation, caffeine 
and vitamin A reduce BPD. Enhancing endogenous anti-oxidant mechanisms through 
supplementation with superoxide dismutase or Clara cell secretory protein has yielded 
encouraging results.  Azithromycin, a macrolide used to treat Ureaplasma infection, also has 
anti-inflammatory properties and has been shown to reduce BPD. Sildenafil reduces the 
echocardiographic markers of pulmonary hypertension associated with BPD, but has not been 
shown to prevent BPD. In animal models and a small phase one study MSC administration 
has resulted in promising results.  Appropriately powered studies with long term outcomes 
are required to assess the efficacy of all these treatments. 
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1. Introduction 
 
Bronchopulmonary dysplasia (BPD) is the most common adverse outcome of very premature 
birth and is associated with chronic respiratory morbidity through to adulthood [1] and 
increased mortality, particularly if it is associated with the development of pulmonary 
hypertension. Affected infants have a poor prognosis with a mortality of 47% within two 
years following the diagnosis of pulmonary hypertension [2].  Between 25 and 40% of 
premature infants with BPD have concomitant pulmonary hypertension [3].   
 
Despite advances in the care of premature infants, including the routine use of antenatal 
corticosteroids, postnatal surfactant and gentler ventilation techniques, the incidence of BPD 
has not significantly changed [4]. This may reflect the survival of more immature infants and 
the changing nature of the disorder. BPD was first described in relatively mature, prematurely 
born infants who had severe respiratory distress syndrome and had received high 
concentrations of inspired oxygen and high ventilator pressures [5]. Histological specimens 
highlighted prominent fibroproliferation. Subsequently, very immature infants who had 
received minimal or no respiratory support in the first week after birth went on to develop 
oxygen dependency at 28 days, so-called “new BPD”. Their lung histology showed more 
homogenous changes, but with arrest of normal alveolar and vascular development [6].  
 
Various definitions have been used to diagnose BPD including supplementary oxygen 
dependency at 28 days or 36 weeks post conception age (PCA). Comparison of use of the 28 
day or 36 week PCA criteria has demonstrated, not surprisingly the later results in smaller 
percentage of infants being diagnosed with BPD, in one series 17% versus 40% [7].  An NIH 
consensus defined BPD as a requirement for supplementary oxygen at 28 days age [8]. Then, 
in those born before 32 weeks of gestational age, the severity of BPD severity was graded 
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according to respiratory support requirement at 36 week PCA, which better predicted long 
term respiratory outcomes [9]. Comparison of that definition with oxygen dependency at 36 
weeks PCA or use of a room air challenge at 36 weeks PCA (a physiological definition of 
oxygen dependency) demonstrated variation in the proportion of infants diagnosed with BPD 
from 32% to 58.6%.  The physiological definition was associated with lowest proportion of 
infants diagnosed [10].  Using an oxygen requirement at any gestational age to diagnose BPD 
is complicated by the increasing use of non-invasive respiratory support such as humidified 
high flow nasal cannula (HHFNC).  Infants may be on air on HHFNC, but without HHFNC 
require supplementary oxygen. The criteria on which to diagnose BPD requires urgent 
revisiting with greater attention to capturing chronic respiratory morbidity.  Compared to 
either 28 weeks or 36 weeks PCA criteria, a one year assessment of respiratory morbidity 
better predicted ongoing respiratory morbidity [11].   For the purpose of this review, 
pragmatically studies which used a supplementary oxygen requirement at 28 days or 36 
weeks PCA to diagnose BPD were included [9].  
 
Our aim was by reviewing the evidence base to determine which emerging therapies might 
reduce BPD and the associated pulmonary hypertension and which were the most promising 
and should be studied in larger trials. We have first discussed the efficacy of more 
longstanding therapies such as corticosteroids, vitamin A and caffeine.   
 
2.  Longstanding therapies 
2.1 Corticosteroids 
Systemically administered corticosteroids reduce BPD whether given in the first 96 hours 
after birth [12], at 7-14 days [13] or after three weeks of age [14].  Unfortunately, they have 
important side-effects including in the first 96 hours an increased risk of gastrointestinal 
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haemorrhage and intestinal perforation, but more importantly increased developmental delay 
at follow-up.  When corticosteroids are administered systemically at older ages, there is no 
significant increase in cerebral palsy but, unlike trials recruiting in the first 96 hours, 
crossover was allowed which may have biased the results.  In view of the many side-effects 
of systemically administered steroids, other options have been explored including inhaled 
corticosteroids (see below) and low dose dexamethasone.  In one RCT, the latter therapy was 
associated with an increase in extubation by 10 days but no significant reduction in BPD [15].   
 
Meta-analysis was undertaken of three trials which compared the efficacy of inhaled to 
systemic corticosteroids in ventilator dependent infants who were very low birth weight ie < 
1500 gms (VLBW) or had a gestational age < 32 weeks and had a postnatal age greater than 
two weeks.  No significant differences regarding reduction in BPD or side-effects were 
demonstrated [16].  A meta-analysis of eight trials which included 232 infants evaluated 
inhaled steroid administration in the first week from birth in infants at high risk of developing 
BPD. Inhaled steroids did not reduce BPD and death, failure to extubate or the total duration 
of mechanical ventilation or oxygen dependency [17].  The Neonatal European Study of 
Inhaled Steroids (NEUROSIS) randomised trial compared the effects of inhaled budesonide 
to placebo administered in the first 24 hours in 863 infants born at 23 to 27 weeks gestation 
who required some form of positive-pressure support [18].  The intervention was delivered 
until the infants no longer required supplementary oxygen or positive pressure support or 
were a postmenstrual age (PMA) of 32 weeks. Inhaled budesonide administration was 
associated with significant reductions in the rate of BPD, surgical closure of a patent ductus 
arteriosus (PDA) and reintubation , but there was a trend towards increased mortality (16.9% 
versus 13.6%) [18].   
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In-tracheal instillation of budesonide has been evaluated using surfactant as a vehicle. One 
hundred and sixteen VLBW infants with severe respiratory distress syndrome (RDS) and  
requiring mechanical ventilation and an inspired oxygen concentration of at least 60% were 
randomised to budesonide suspension with surfactant or surfactant alone [19].  The 
proportion of infants who survived without BPD was significantly higher in the budesonide 
group.  There were no clinically significant adverse effects were reported [19] and follow at 
between two to three years demonstrated no significant differences in physical growth or 
neurological examination results [20].  A multicentre RCT was then undertaken including 
265 infants with severe RDS.  The budesonide group had a lower incidence of BPD or death 
(RR 0.58, 95% CI 0.44-0.77) and the number needed to treat was 4.1 [21].   
 
2.2   Caffeine 
The Caffeine for Apnoea of Prematurity (CAP) trial randomized infants if their clinicians 
thought them to be candidates for methylxanthine therapy for prevention or treatment of 
apnoea and/or facilitation of removal of an endotracheal tube in the first 10 days after birth.   
Two thousand and six infants with birth weights between 500 to 1250 gm were recruited.  
The primary outcome of death or neurodevelopmental disability (NDI) was determined at 18 
to 21 months.  The incidence of death or NDI was significantly lower in the caffeine group 
(40.2% versus 46.2%) and who also had a lower BPD rate, a secondary outcome (36.3% 
versus 46.9%) [22]. At five years, there were no significant differences in survival without 
disability [23].  Methylxanthines inhibit adenosine receptors that have been linked to anxious 
and aggressive behavior in mice with targeted deficiencies of each of those receptors [24, 25], 
thus the results of the CAP trial are reassuring.  Caffeine acts by increasing central drive and 
by lowering the threshold of response to hypercarbia as well as by stimulating diaphragmatic 
contractility and prevention of a phragmatic fatigue, it also has a diuretic action [26].  
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Caffeine use was associated with a lower PDA incidence likely due to the increased diuresis 
and improved cardiac and pulmonary function [27], which may in part have been responsible 
for the reduction in BPD.  It also has anti-inflammatory properties; for example in an animal 
model of hyperoxia caffeine reduced the influx of inflammatory cells into the lung and 
attenuated hyperoxia-induced upregulation of pro-inflammatory markers [28].  Caffeine may 
also inhibit Smad signaling and TGF-β1 regulated genes in airway remodeling [29].  Post hoc 
analysis of the CAP trial has demonstrated infants receiving respiratory support appeared to 
derive more neurodevelopmental benefit from caffeine.  Early initiation of caffeine therapy 
may be associated with a greater reduction in ventilation duration [30].       
 
2.3 Vitamin A 
Vitamin A is a group of fat-soluble compounds which maintain the integrity of epithelial cells 
of the respiratory tract. In a lamb model of vitamin A deficiency, histopathological changes 
included necrotizing tracheobronchitis and squamous metaplasia.  Restoration of vitamin A to 
replete levels resulted in more normal surface epithelium in the conducting airways [31].  
Premature infants are vitamin A deficient [32] and a prospective study demonstrated lower 
vitamin A levels in those who subsequently developed BPD [33].  
 
A Cochrane review of vitamin A supplementation in very low birth weight infants or those 
born before 32 weeks of gestational age identified 11 trials including more than 1500 infants 
in total. Vitamin A administration was associated with a small, but significant reduction in 
BPD as diagnosed at 36 weeks PCA (RR 0.87, 95% CI 0.77 to 0.99), with the number needed 
to treat of 11 (95% CI 6 to 100) [34].  There was, however, considerable heterogeneity in the 
trials with regard to their inclusion criteria and intervention, including the birth weight, 
ethnicity, baseline vitamin A status, route of vitamin A supplementation (intramuscular, 
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intravenous in lipid emulsion, or enteral), and the vitamin A dose given.  The only trial 
(n=807) reporting long term neurodevelopmental follow up to 18 and 22 months 
demonstrated no significant differences in outcomes [35]. It has been suggested that BPD 
might be reduced with the combination of vitamin A and inhaled nitric oxide [36].  The 
study, however, was not randomized and the data analysed retrospectively [36].   
 
3. Emerging therapies 
3.1. Superoxide Dismutase Replacement 
Superoxide dismutases (SODs) catalytically convert the superoxide free radical to oxygen 
and hydrogen peroxide, hence protecting the lung tissue from oxidative injury caused by free 
radicals in a hyperoxic environment [37].  The enzymatic activity of SODs are similar in the 
premature and mature human lung [38]. Transgenic mice modified with knock-out of genes 
encoding for SODs had disruption of alveolar development at baseline and an exaggerated 
poor response to oxidative stress [39].  Conversely, transgenic mice which over-expressed 
human SODs, when exposed to hyperoxia had less pulmonary neutrophil influx and oxidized 
glutathione and preservation of alveolar surface and volume density compared with wild-type 
littermates [40].  In animal models of prematurity and pulmonary hypertension, treatment 
with intra-tracheal preparations of SODs protected against acute lung injury [41-43]. 
 
In a study of 33 infants with a birth weight between 600 and 1200g, those treated with intra-
tracheal recombinant human CuZnSOD (rhCuZnSOD) every 48 hours for seven days had 
increased activity of the enzyme in their serum, tracheal aspirate and urine. Markers of lung 
injury in the tracheal aspirate were lower in the treated infants [44]. Subsequently, in a multi-
centre randomised control trial (RCT), 302 infants were treated with either intra-tracheal 
rhCuZnSOD or placebo every 48 hours while they remained mechanically ventilated until a 
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postnatal age of 28 days.  There were no statistically significant differences in BPD, death, or 
the combined outcome of BPD and death.  In a subset born prior to 27 weeks of gestation, 
however, those treated with rhCuZnSOD received fewer asthma medications (p=0.01) and 
had lower rates of emergency room visits (p=0.01) and hospitalization (p=0.05) at follow up 
[45]. Despite those promising results, there have been no further clinical trials reported. 
 
3.2. Macrolides 
A systematic review highlighted a significant association between pulmonary colonisation 
with Ureaplasma and BPD [46].  Macrolides such as erythromycin, clarithromycin and 
azithromycin are used to treat Ureaplasma infections [47].  
 
A systematic review was undertaken of randomised or quasi-randomised studies of either 
prophylactic or therapeutic erythromycin in preterm or low birth weight (LBW) infants [48] 
with either unknown U Ureaplasma status or proven positive by culture or polymerase chain 
reaction (PCR). Only two small RCTs were identified both involving intubated infants less 
than 30 weeks of gestation; neither showed a statistically significant reduction in BPD or 
death or the combined outcome [48].   
 
Clarithromycin [49], either prophylactically or in infants with Ureaplasma has not been 
shown to prevent BPD [50]. In animal models of colonization of the respiratory tract by 
Ureaplasma, both azithromycin and clarithromycin accumulated more in the lung epithelial 
lining fluid and alveolar macrophages than erythromycin [49, 51].  
 
Azithromycin, however, might reduce BPD not only by its anti-microbial action against 
Ureaplasma spp., but also via its immunomodulatory and anti-inflammatory activities.  In 
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murine models of inflammatory lung disease, azithromycin reduced leukocyte infiltration of 
the lungs and inflammatory cytokines [52] In addition, administration of azithromycin 
blocked release of pro-inflammatory cytokines (IL-6 and IL-8) in cells acquired from tracheal 
aspirates of preterm infants [53]. In a RCT of 33 infants with Ureaplasma spp as detected by 
PCR analysis of tracheal aspirates, azithromycin treatment was associated with a reduction in 
BPD (odds ratio (OR) 0.026, 95% confidence intervals (CI) 0.001 to 0.618) [54].  The dosage 
of azithromycin used in the study was 10mg/kg for seven days and then 5mg/kg subsequently 
for a maximum of six weeks [54]. Pharmacokinetic data, however, suggest that the optimal 
dose may be higher [55]. A systematic review of studies of prophylactic, intravenous 
azithromycin versus placebo included 310 infants born at less than 30 weeks of gestational 
age or of low birth weight. Azithromycin administration was associated with a reduction in 
BPD (relative risk (RR) 0.83, 95% CI 0.71 - 0.97) and the combined outcome of BPD and 
death, but no significant change in mortality [49]. In a subsequent systematic review of 11 
trials which included 473 infants azithromycin was demonstrated to reduce BPD in extremely 
low birth weight (ELBW) infants (RR 0.83, 95% CI 0.72 - 0.98, p=0.02) [56]. There was no 
significant difference in the incidence of elevated liver enzymes, but there were four cases of 
hypertrophic pyloric stenosis [56].  
 
Both azithromycin and erythromycin have been linked to the development of idiopathic 
hypertrophic pyloric stenosis, but the results are from a retrospective study.  The association 
was strongest if the exposure occurred in the first two weeks after birth [57]. There are no 
reported cases of cardiac side effects as seen in adults, in infants treated with azithromycin 
[56]. 
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3.3. Clara Cell Secretory Protein 
Clara cell secretory protein (CCSP) is predominantly secreted by mucosal epithelial cells of 
the airway.  CCSP is synonymous with Clara cell 10kD protein and CC16, which reflect its 
low molecular weight of 15.84kD.  Endogenous CCSP has potent anti-inflammatory activity, 
inhibiting pro-inflammatory cytokines and neutrophil infiltration. In addition, it inhibits 
secretory phospholipase A2, an enzyme which degrades surfactant and facilitates 
prostaglandin biosynthesis [58]. Transgenic mice deficient in CCSP have been demonstrated 
to have exaggerated pulmonary inflammatory responses to hyperoxia and higher mortality 
rates [59].  Intra-tracheal treatment with exogenous CCSP tended to improve gas exchange 
and lung compliance in newborn piglets exposed to a hyperoxic injury [60]. A study in a 
premature lamb model found that treatment with synthetic recombinant human Clara cell 
secretory protein (rhCC10), increased surfactant protein and VEGF levels [61].  Co-
administration of surfactant and rhCC10 significantly reduced RDS-induced lung and 
systemic inflammation in a lamb model compared to surfactant alone [62]. 
 
Levels of CCSP increase with increasing gestational age in human infants [63]. CCSP 
concentrations have been demonstrated to correlate negatively with the concentration of 
inspired oxygen required by preterm infants with RDS [64].  In a prospective study, CCSP 
levels in tracheal aspirates were lower from day one after birth in infants who developed BPD 
compared to those who did not [65].   
 
One study has investigated the efficacy of intra-tracheal administration of rhCC11300. In 22 
infants with birth weights between 700 and 1300 gms, there was no statistically significant 
reduction in BPD (RR 0.50, 95% CI 0.06 to 4.33) [64].  A Cochrane review identified only 
one pilot study [66].  A Phase II clinical trial (NCT01941745) is underway to investigate the 
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pharmacokinetics, safety, tolerability and anti-inflammatory effects of a single, intra-tracheal 
administered dose of rhCC10 [67]. 
 
3.4. -1 Protease Inhibitor 
Elastase is a proteolytic enzyme released as a consequence of oxidative damage by free 
radicals. -1 Protease Inhibitor (-1PI) inhibits elastase; endogenous levels are lower in 
prematurely born infants compared to those born at term and may be particularly low in those 
who develop BPD [68]. In a mouse model, genetically modified to express a human serine 
elastase inhibitor (elafin), compared to wild type controls there was a blunted inflammatory 
response to high supplementary oxygen and ventilator induced lung injury. This was 
indicated by NF-κB activation, influx of neutrophils and monocytes, TGF-β activation and 
apoptosis and preserved matrix elastin [69].  
 
Meta-analysis of two RCTs of -1PI versus placebo which included a total of 195 infants, 
demonstrated a small, but statistically significant effect on 28 day oxygen requirement (RR 
0.80 (95% CI 0.65 to 0.98)), but no statistically significant difference in oxygen requirement 
at 36 weeks PCA [70].  In one of the two trials, a secondary outcome of pulmonary 
haemorrhage was lower in the treatment group (RR, 0.22; CI, 0.05 to 0.98) which suggests -
protease may have further effects on the lung which could potentially contribute to BPD 
development [71].  No subsequent studies have been performed to verify those results. 
 
3.5. Pentoxifylline 
Pentoxifylline is a synthetic methylxanthine derivative.  It has anti-inflammatory, anti-fibrotic 
and immunomodulatory properties. Unlike caffeine and theophylline, at a therapeutic dose 
pentoxifylline does not cause significant bronchodilation, central nervous stimulation, or 
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cardiac side effects [72]. It causes erythrocyte phosphodiesterase inhibition with down-
regulation of inflammatory cytokines, including TNF- and ICAM-1, which are implicated in 
the development of BPD [73].   
 
Neonatal rats exposed to hyperoxic lung injury treated with pentoxifylline had reduced fibrin 
deposition (a correlate of severity of lung injury) and prolonged survival, although levels of 
TNF-α were unchanged [74].  Another study of treated neonatal rats demonstrated decreased 
lung oedema and macrophage infiltration, with increased lung anti-oxidant enzyme activity 
(superoxide dismutase, catalase and glutathione peroxidase). Additionally, pulmonary 
vascularization was improved with enhanced VEGF protein expression [75]. A model of 
volume induced lung injury in mechanically ventilated piglets showed a reduction in platelet 
activating factor (a proxy for inflammation) in the lungs of the pentoxifylline treated group. 
There was also a reduction in lung oedema and lung tissue myeloperoxidase activity, a 
measure of neutrophil presence [76]. 
  
The efficacy of pentoxifylline in the prevention of BPD has been evaluated in two clinical 
settings, prematurity and sepsis. In VLBW infants, a pilot RCT of nebulized pentoxifylline 
versus placebo with 100 participants showed a significant difference in the risk of BPD (OR: 
0.32; CIs 0.11 to 0.94; p = 0.039). There were, however, methodological weaknesses in the 
RCT including the assessors were not blinded to treatment group and there was complete 
outcome reporting in only 65% of those recruited [77]. When the data were analysed on an 
intention to treat basis the differences no longer reached statistical significance [78]. A 
subsequent RCT of 80 infants with a gestational age less than 28 weeks, with more robust 
blinding and 100% outcome data, did not show a statistically significant difference in the 
incidence of BPD  or the total duration of oxygen therapy (p=0.75) [79].  In the setting of 
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neonatal sepsis pentoxifylline, in addition to antibiotic therapy, did not reduce BPD (RR 1.50, 
95% CI 0.45 to 5.05) [80].  
 
3.6. Melatonin 
Endogenous melatonin protects against oxidative stress both by direct scavenging of the 
highly reactive hydroxyl free radical and indirectly by modulation of anti-oxidant enzymes 
[81, 82]. Preterm infants are relatively melatonin deficient [83]. In rat models subjected to 
oxidative stress, melatonin treated animals showed an increase in anti-oxidant enzymes  
(superoxide dismutase, catalase and glutathione peroxidase) activity, reduction in  neutrophil 
influx and a more normal alveolar architecture versus the interstitial fibrosis seen in untreated 
controls [84, 85].  
 
A study of 110 infants born less than 32 weeks of gestational age with RDS and supported 
with a range of ventilation modes (conventional ventilation, pressure-support ventilation, 
volume guarantee and high-frequency oscillatory ventilation) found that those given 
melatonin had a reduction in inflammatory cytokines IL-8 and TNF-, all associated with the 
development of BPD. Additionally, the treated group had significantly lower maximum 
inspired oxygen concentrations, peak inspiratory pressures, peak end expiratory pressures and 
oxygenation index [86].  In an extension of that study, the authors assessed 120 infants with 
RDS born at less than 32 weeks of gestation. No infants in the melatonin group, but eight 
infants in the control group developed BPD (this difference was not statistically significant).  
Those with BPD, however, had statistically significant higher levels of initial inflammatory 
markers (IL-6, IL-8 and TNF-), which the group had previously shown to be ameliorated by 
melatonin treatment.  No adverse effects of melatonin treatment were reported [87]. 
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3.6. Inositol 
Inositol, an essential six-carbon ring sugar, is a component of the group of phospholipids 
called phosphoinositides and glycosyl-phoshatidylinositols and is involved in surfactant 
maturation. Infants with a premature drop in inositol levels have been demonstrated to 
develop more severe RDS [88]. In a preclinical rat model, supplementation of inositol 
normalised phospholipid levels in deprived rat pups [89]. 
 
A Cochrane review of four RCTs which included 343 infants showed no statistically 
significant difference in BPD at 28-30 days with repeated doses of inositol versus placebo 
(RR 0.78, 95% CI 0.54 to 1.13) nor in BPD at 36 to 38 weeks PCA [90, 91].  In a study of 65 
infants, however, who received a single dose of inositol, there was no statistically significant 
difference in the relative risk of BPD at 36 weeks PCA (RR (2.74, 95% CI 0.88 to 8.48; P = 
0.08) [92].  
 
3.8. Cysteine and N-acetyl cysteine 
L-cysteine is a precursor to the anti-oxidant, glutathione.  Deficiency in L-cysteine in the 
prematurely born infant may lead to increased susceptibility to an oxidative insult.  Delivery 
of cysteine has practical issues due to solubility and stability, thus its more stable precursor 
N-acetyl cysteine is used [93]. 
 
A Cochrane review assessed the efficacy of supplementation of parentally fed infants with 
cysteine or N-acetyl cysteine with secondary outcomes of oxidative injury including BPD 
[94].  No studies reported on the impact of cysteine on BPD.  N-acetyl-cysteine did not 
reduce BPD (n=328, RR 0.99, 95% CI 0.76 to 1.29), nor increase plasma levels of cysteine.  
In one study, the plasma concentration of cysteine was lower in the N-acetyl cysteine treated 
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group [95].  
 
3.9. Allopurinol 
Xanthine oxidase is implicated in the generation of oxygen free radicals under hypoxic-
ischaemic conditions. Allopurinol is a xanthine oxidase inhibitor. In a RCT, 400 infants with 
a gestational age between 24 and 32 weeks were allocated to either a seven day course of 
allopurinol or placebo.  At recruitment, the infants who subsequently developed BPD had 
significantly higher levels of hypoxanthine.  There were, however, no statistically significant 
differences in BPD or other sequelae of prematurity between the two groups [96]. 
  
3.10. Cimetidine 
Cimetidine is an inhibitor of the cytochrome P450 enzyme system. Cytochrome P450 
facilitates mono-oxygenation reactions which produce oxygen free radical species. In a rat 
model, induction of cytochrome P450 reduced survival under oxidant stress. Furthermore in 
rabbits, inhibitors of cytochrome P450 significantly reduced lung oedema and prevented the 
reperfusion-related increase in lung microvascular permeability, but there was no reduction in 
free radicals in treated rabbits. In a lamb model of hyperoxic lung injury, cimetidine was 
demonstrated to be an effective protection against lung injury. In contrast to the rabbit model, 
the oxidized glutathione level was significantly lower in cimetidine-treated lambs, suggestive 
of reduced oxygen free radicals [97]. 
 
An RCT of intravenous cimetidine or placebo in 84 infants with a birth weight less than 
1250g was stopped prematurely due to increased incidence of death and severe 
intraventricular haemorrhage in the treatment arm. At that point, there were no statistically 
significant differences in BPD or other outcomes [98]. 
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4. Pulmonary vasodilators 
Animal studies of placental insufficiency and prematurity have demonstrated derangement of 
the nitric oxide - cyclic guanosine monophosphate signaling pathway, which is associated 
with abnormal vascular responses.  Both quantitative immunoblot analysis and semi-
quantitative immunohistochemistry highlighted less endothelial nitric oxide synthase (eNOS) 
protein in the endothelium of small intrapulmonary arteries and epithelium of small airways 
of preterm lambs that had been mechanically ventilated for three weeks compared to lambs 
born at term [99]. Those results support the hypothesis that decreased eNOS in the pulmonary 
circulation and respiratory tract may contribute to the pathophysiology of BPD [99]. 
Pulmonary vasodilators then could have efficacy in the prevention of BPD.   
 
4.1 Inhaled nitric oxide 
Inhaled nitric oxide (iNO) selectively decreases pulmonary vascular resistance and hence 
improves oxygenation. It also has anti-inflammatory properties and promotes cell and blood 
vessel growth in the immature lung. Infants dying with BPD have been demonstrated to have 
disrupted pulmonary vasculature and hence it has been proposed that iNO might reduce BPD. 
Indeed in an animal model, iNO stimulated angiogenesis and alveolarisation [100]. 
 
Meta-analysis of 14 randomised trials demonstrated that the effect of iNO in prematurely 
born infants regarding prevention of BPD was dependent on the timing of administration and 
the population studied [101]. Nine trials of early rescue treatment of infants based on oxygen 
criteria demonstrated no significant effect of iNO on mortality or BPD.  Similarly, routine use 
of iNO in infants with pulmonary disease demonstrated no significant reduction in BPD or 
mortality.  One RCT, however, highlighted that early, prolonged, low dose iNO did not 
reduce BPD in infants who required invasive or non-invasive respiratory support [102] nor 
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did it improve outcomes at follow-up [103].  A further RCT [104] confirmed that iNO given 
non-invasively in the first 72 hours after birth did not reduce BPD.  Infants receiving iNO all 
born less than or equal to 28 weeks of gestation and requiring mechanical ventilation at 7 to 
14 days were randomised to receive up to five doses of surfactant or sham instillation every 
one to three days [105].  Although the surfactant administration was well tolerated it did not 
improve survival without BPD at 36 or 40 weeks.  Inhaled nitric oxide has been given to 
infants with pulmonary hypertension and BPD with anecdotal success. iNO administration in 
a small series resulted in reduction in pulmonary artery pressures to near normal levels [106].   
   
4.2 Sildenafil 
Phospodiesterase-V is highly expressed in the lung and metabolises cyclic guanosine 
monophosphate (GMP), a regulator of NO-mediated vascular relaxation.  Sildenafil is a 
phosphodiesterase-V inhibitor and hence increases cGMP concentrations and results in 
pulmonary vasodilation. Sildenafil acts as a vasodilator both in the pulmonary vasculature 
and, to a lesser degree, systemically.  
 
In rat models of hyperoxia-induced BPD, sildenafil administration improved alveolar growth 
and lung angiogenesis. Additionally, the animals treated with sildenafil had less right 
ventricular hypertrophy and reduced echocardiographic signs of pulmonary hypertension 
[107, 108]. In lambs with experimental pulmonary hypertension, both enteral and aerosolized 
sildenafil resulted in dilation of the pulmonary vasculature and augmentation of the 
pulmonary vascular response to iNO [109, 110]. 
 
There is limited information regarding the use of sildenafil to prevent BPD. In a pilot RCT of 
20 infants, four weeks of oral sildenafil solution (3mg/kg/day) was compared to placebo 
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commenced on day seven in mechanically ventilated infants of less than 28 weeks of 
gestational age. There was no statistically significant difference in BPD at 36 weeks PCA, but 
a non significant trend for the sildenafil treated group to require more hours of mechanical 
ventilation and postnatal steroid treatment and they also had a higher respiratory-related 
mortality [111].   
 
In pulmonary hypertension associated with existing BPD, small retrospective case series have 
demonstrated benefit from sildenafil with regard to echocardiographic assessments of 
pulmonary hypertension [3, 112, 113], but not always associated with clinical improvement 
[112]. One retrospective study with long term follow up of 22 infants showed that sildenafil 
was well tolerated with long term improvement in pulmonary hypertension, although 20% of 
the study population died [114]. In a recently reported, retrospective study, 12 of 18 infants 
with BPD and related pulmonary hypertension were treated with sildenafil, five received 
sildenafil and bosentan and another bosentan only [115]. The median follow-up was two 
years and the improvement in pulmonary hypertension was maintained at the last follow-up 
with a better survival rate (95%) than previously reported. The lack of control groups and/or 
limited follow up, however, reduces the generalisability of the results to clinical practice.  In 
addition, the optimum dose of sildenafil has not been robustly established and the absorption 
of drug when given orally is variable in prematurely born infants.  
 
4.3 Bosentan 
Bosentan is an endothelin-A (ETA) and endothelin-B (ETB) receptor antagonist, which 
prevents potent vasoconstriction caused by endothelin 1 binding to ETA and ETB receptors. 
It has been used extensively in adult patients with pulmonary hypertension. There is no 
published evidence for its use in prematurely born infants at risk of BPD.  A Cochrane review 
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of two small RCTs of bosentan in infants born after 34 weeks of gestation with persistent 
pulmonary hypertension concluded that there was inadequate evidence to support the use of 
bosentan either as stand-alone therapy or as an adjuvant to inhaled nitric oxide [116]. There 
are single case reports of the efficacy of bosentan in BPD associated pulmonary hypertension 
[117, 118].  
 
4.4 Prostacyclin 
Prostacyclin is produced in the vascular endothelium and causes smooth muscle relaxation. 
Pulmonary hypertension in the neonatal and paediatric population is associated with 
decreased prostacyclin synthesis [119].  The usefulness of prostacyclin administration such as 
epoprostanol, however, is limited by its short half life and hence a continuous infusion is 
required via a central line.  Newer synthetic analogues such as iloprost and treprostinil have a 
longer half-life. There are no reports for its use as a primary preventative measure for BPD. 
The evidence for its efficacy in neonates with BPD associated with pulmonary hypertension 
is limited to case reports [117, 120]. 
 
5. Stem cells 
There are some promising early results of the potential effect of stem cells on BPD.  
Hyperoxia induced BPD in neonatal rats is associated with decreased circulating and resident 
mesenchymal stem cells (MSC) [121]. Administration of bone marrow derived MSCs or 
multipotent stromal cells prevented the compromised alveolar and vascular development in a 
murine hyperoxia induced BPD model [121]. Treatment with MSC conditioned media after 
hyperoxia might then reverse the disease [122]. Bronchioalveolar stem cells (BASCs) are an 
adult lung stem cell population capable of self-renewal and differentiation in culture [123]. 
They proliferate in response to bronchiolar and alveolar lung injury in vivo [123].  Systemic 
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treatment of neonatal hyperoxia-exposed mice with MSC and MSC-conditioned media 
resulted in an increase in BASCs.  The authors suggested MSCs and MSC-derived factors 
might stimulate BASCs to play a role in the repair of lung injury in BPD [123].  A source of 
stem cells is the human cord.  In an oxygen induced model of BPD, human cord derived 
perivascular cells (PCs) or cord blood derived MSCs delivered into the airway of rat puts 
resulted in rescued lung function and structure.  Cell engraftment was low suggesting the PCs 
and MSCs may act via a paracrine effect.  Assessment at six months showed no adverse lung 
effects [124] In a rat model, hyperoxia exposure led to air space enlargement, loss of lung 
capillaries and low expression of VEGF and eNOS.  Transplanted endothelial progenitor 
cells, when combined with iNO, resulted in improved alveolarisation, microvessel density 
and upregulation of VEGF and eNOS proteins [125].   In a rat model of BPD induced by 
perinatal inflammation and hypoxia administration of MSCs improved vascular density and 
reduced TNF, IL-6 and collagen density to normoxic levels [126].  Thus, MSCs attenuated 
perinatal inflammation and hypeoxia induced defective alveolarisation and angiogenesis and 
reduced lung fibrosis [126].   A phase 1 dose-escalation trial has been undertaken to assess 
the safety and feasibility of a single, intratracheal transplantation of human umbilical cord 
blood (hUCB) derived MSCs in preterm infants at high risk of BPD.  Nine infants, mean 
gestational age of 25.3 weeks were included in the trial at a mean of 10.4 days.  The first 
three patients were given a low dose (1x107 cells/kg) and the next six a high dose (2x107 
cells/kg).  Comparison was made to historical case-matched infants.  The treatment was 
reported to have been well tolerated and no serious side-effects were reported.  Levels of IL-6 
IL-8, TNF, metalloproteinase-9 and transforming factor β1 in tracheal aspirates at day 
seven were significantly lower than at baseline.  BPD severity was lower in the transplant 
recipients [127].  Those promising results should be further investigated in appropriately 
designed studies. 
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6.5. Conclusion 
There are several emerging therapies which reduced BPD or associated pulmonary 
hypertension, but none have been robustly tested in large RCTs with long term follow-up. 
Superoxide dismutase replacement has been shown in one trial to improve long term 
respiratory outcomes in an immature subgroup, but not to reduce BPD. Azithromycin does 
reduce BPD in confirmed Ureaplasma spp. infection and in the absence of positive isolates. 
Additional work, however, is needed to clarify the optimal dosage for neonates and determine 
whether there are no adverse gastro-intestinal side effects. Recombinant Clara cell protein 
and mesenchymal stem cells appear promising new therapies. There is insufficient evidence 
at present to support routine use of pentoxifylline, melatonin, inositol and N-acetyl-cysteine, 
allopurinol or cimetidine. Further studies are required to determine whether pulmonary 
vasodilators might prevent BPD and evaluate their efficacy in the management of infants 
with pulmonary hypertension associated with BPD.    
 
 
 Expert Opinion (Table) 
 
 
Potentially interesting results have been demonstrated with the anti-oxidant, recombinant 
superoxide dismutase (SOD), but these have not encouraged other studies, perhaps as 
multiple doses of SOD had to be given intra- tracheally. In animal models, augmentation of 
the endogenous anti-inflammatory pathway with recombinant analogue of Clara cell 
secretory protein, rhCC10 has yielded promising results, but this has not yet been translated 
into important clinical outcomes. A phase one study of mesenchmal stem cells yielded 
promising results with no reported adverse effects.  Only nine infants, however, were 
included and received a single dose given intracheally.  This therapy merits further testing. 
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Azithromycin, which acts as both an anti-inflammatory and anti-bacterial agent with efficacy 
against Ureaplasma, reduced BPD when used prophylactically and in those with confirmed 
Ureaplasma colonization.  Caution, however, is advised, as azithromycin has been associated 
with the development of hypertrophic pyloric stenosis.   Meta-analysis of supplementation 
with vitamin A has demonstrated reduction in BPD, but no change in longer-term outcomes, 
further emphasising that BPD is not an appropriate outcome for RCTs assessing agents to 
prevent the chronic respiratory morbidity of prematurely born infants. Indeed, there should be 
focus on therapies which should reduce chronic respiratory morbidity than BPD.  Infants with 
BPD associated pulmonary hypertension have a poorer prognosis. There is an urgent need to 
determine which pulmonary vasodilators might improve the outcome of those BPD infants 
with pulmonary hypertension.  
 
 
 
ARTICLE HIGHLIGHTS 
 
 Azithromycin reduces BPD when used prophylactically and in infants colonized with 
Ureaplasma 
 In animal models of BPD recombinant Clara cell secretory protein reduced lung 
inflammation.  
 An RCT of recombinant superoxide dismutase demonstrated improved long term 
respiratory outcomes, such as reduction in asthma medications and hospitalization 
with respiratory illness 
 Meta-analysis highlighted vitamin A reduced BPD, but not long term outcomes and 
there was considerable heterogeneity of included trials. 
 Sildenafil improved echocardiographic markers of pulmonary hypertension associated 
with BPD, but did not prevent BPD.   
 Administration of mesenchymal stem cells have improved short term outcomes in 
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animal models and in a small phase one study.   
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